TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Negative predictive value of CGM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acetylsalicylic acid resistance rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: GCSI score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Any Adverse Device Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Time to cervical ripening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change of Limb Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single leg vertical countermovement jump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single leg horizontal countermovement jump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum level of proalbumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Actual hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Discomfort evaluation with Wong-Baker
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Discomfort evaluation with heart beat and oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in internal carotid artery blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: score of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Resuscitation decision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax of YM150
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of YM150
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Global Rating of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Difference Between WOMAC Pain Subscale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Difference Between WOMAC Physical Function Subscale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Glucose response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HIV Viral Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of TGF-β1, EGF, and VEGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive outcome after XRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chromameter redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean ratio of detecting glioblastoma cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: changes in mean airway pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes in tidal and minute volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes in breathing frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in log10 plasma HIV-1 RNA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in QIDS-C16 Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety of autologous EBV-specific CTLs
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of DLTs During Cycle 1
Endpoint domain: Adverse events/effects
Primary endpoint: Documented, Confirmed Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of challenge-proven food allergy at 12 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of definite food allergy or tolerance at 6 years of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUC(0-t) of fruquintinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-inf) of fruquintinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of fruquintinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response evaluated by Vancouver Scar Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: radiographic change of the spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DCE-MRI Derived Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bech-Rafaelsen Mania Rating Scale (BRMS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Children's Yale-Brown Obsessive-Compulsive Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics for pravastatin (Cmax and AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of treated subjects with closed fistulae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: CNS progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: Difference in hunger before to after meal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Five times sit to stand (5XSST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed up and go (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in urinary NTx level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak Estimated Blood Alcohol Concentration (Peak eBAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Heavy Episodic Drinking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasmatic 8-isoprostane concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder status after 8 weeks treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom score of pain or burning in the upper abdomen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with circulating free tumor DNA mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of participating survivors that would recommend the program to other survivors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean rating of participating survivor intervention satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of planned intervention modules completed by participating survivors
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum Tolerated Dose (MTD) of gemcitabine plus dasatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-perceived pain and disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Altered TMEM219 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Normal performance curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self Reported Binge Drinking Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants With Treatment-Emergent Adverse Experiences (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: change from baseline functional performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Uroflow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: change in Hepatitis C-virus load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful recording of a His bundle potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change From Baseline in uGAG Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Marginal Bone Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with LCX occlusion as culprit artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peripheral endothelial dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physical activity (daily steps)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Power of Attention Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Participants With Adverse Events Leading to Study Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence free Survival (RFS)
Endpoint domain: Mortality/survival
Primary endpoint: Perceived Effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of 18F-NaF PET for bone metastasis detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of 18F-NaF PET for bone metastasis detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of 18F-NaF PET for bone metastasis detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Acute Urinary Retention (AUR) relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in systolic or diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline to Treatment for Constructive Engagement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline to Treatment for Passive Engagement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline to Treatment for Other Engagement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline to Treatment for Non Engagement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline to Treatment for Pleasure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time for blood flow to return to baseline after cold exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Time to Disposition
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: time of cell cleavage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with allergic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with chronic inflammatory disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC[0-t]) After Single Dose Administration of Gepotidacin 1500 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) After Single Dose Administration of Gepotidacin 1500 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for identification of bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HCQ dose modification and ability to complete course
Endpoint domain: Adverse events/effects
Primary endpoint: discontinuation of HCQ before end of course
Endpoint domain: Adverse events/effects
Primary endpoint: Average number of chest radiographs per patient-day
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Gout
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cataract
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gallstone disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dementia and mild cognitive impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of all strokes leading to hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of bleeding leading to hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Residual constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Small LDL particle concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Positive predictive value of vision screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival to 36 weeks postmenstrual age free of severe brain injury
Endpoint domain: Mortality/survival
Primary endpoint: Survival without moderate or serious disability
Endpoint domain: Mortality/survival
Primary endpoint: AUCτ,ss of Amlodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,ss of Amlodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants That Display Ioflupane-positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Follow-up outcomes in pregnancy after Assisted Human Reproduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Patient-reported experience measures (PREM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient-reported outcome measures (PRO)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Count of PDX models developed from patient samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Radiographic Progression-Free Survival Rate (rPFS) at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Median Overall Radiographic Progression-free Survival (rPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Safety of the procedure from initiation of treatment through hospital discharge
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of the treatment through Week 12
Endpoint domain: Adverse events/effects
Primary endpoint: Number of FM patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OZ439 AUC(0-168)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Piperaquine AUC(0-168)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Piperaquine t1/2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sinonasal quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Implant motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Plasmodium falciparum molecular markers of antifolate resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in nasopharyngeal pneumococcal resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in commensal E. coli resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Patients Who Responded to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dopamine D2/D3 receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional limitations on activities of daily living
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free Survival at 36 Months
Endpoint domain: Mortality/survival
Primary endpoint: Sodium excretion efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Multiple Adverse Cardiovascular Events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Patient Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: total atrial conduction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of objective response (complete or partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epidural use
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline Mental health distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline Neo-angiogenesis (Microvessel Density)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Collagen Formation (Collagen Content)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Myofibroblasts Formation (Myofibroblasts Content)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse drug events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving an Undetectable Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced Falls
Endpoint domain: Adverse events/effects
Primary endpoint: Brain neuroimaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 7-day Point Prevalence Smoking Abstinence at 6-month Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day Point Prevalence Smoking Abstinence as Bioverified by Breath Carbon Monoxide < 4 Parts Per Million
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean daily pain rating score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIQ-Total score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Participants With Undetectable Plasma HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Main adverse cardiac events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of correct answers of an emotional facial expression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cor Family-related Serious Adverse Device Effect (SADE)-Free Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of targeted adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Functionally Correlated Neural Substrates of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: blood measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Heart Rate in Response to IV Cocaine Infusion With and Without CLAV Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Blood Pressure in Response to IV Cocaine With and Without CLAV Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Electrocardiogram (ECG) Following IV Cocaine With and Without CLAV Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Biological toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: TOF ratio of 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appearance of hematoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Onset of effective analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRV parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extracorporeal circulation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aortic clamping time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyaluronic acid levels in blood before surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: healing of visceral attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: healing of polyadenopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: normalisation of biological abnormal values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percent Change in the Inflammatory Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Percent Change in the Non-inflammatory Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Weight Loss Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient outcome related to tumor genotype
Endpoint domain: Mortality/survival
Primary endpoint: patient outcome related to constitutional genotype
Endpoint domain: Mortality/survival